Recce Pharmaceuticals

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Oil & Gas

Real Estate

TMT

Pharnext

MCap

EUR1m

Last close

EUR0.10

▲ 0.06 (150.00%)

Actinogen Medical

MCap

AUD48m

Last close

AUD0.03

▲ 0.01 (50.00%)

DFR Gold

MCap

CAD13m

Last close

CAD0.10

▲ 0.03 (42.86%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Recce Pharmaceuticals (ASX: RCE)

Currency in AUD

Last close As at 27/09/2023

AUD0.47

▲ −0.04 (−7.84%)

Market capitalisation

AUD96m

Overview
Price performance
Financials
Research
Thematics

Recce Pharmaceuticals is an Australian company developing its novel, broad-spectrum synthetic polymer anti-infective drugs for the treatment of several infectious diseases, including sepsis (Phase II-ready), burn wound infections (Phase I/II) and urinary tract infections.

The WHO estimates that sepsis leads to c 11 million deaths each year. Sepsis affects 1.7 million people in the United States annually and has been reported as the country’s most expensive condition in aggregate to treat in the hospital, costing the healthcare system US$57bn in inpatient costs. We view significant opportunities for treatments that may reduce morbidity or hospital utilisation. Recce had a gross cash balance of A$1.6m at the end of June and is seeking to raise A$12–15m.

Latest Insights

Healthcare |
Update

23.08.23

Recce Pharmaceuticals — R327 progressing in rapid infusion study

Healthcare |
Update

11.07.23

Recce Pharmaceuticals — Gearing up for more R327 studies

Healthcare |
Initiation

08.03.23

Recce Pharmaceuticals — Seeking a breakthrough in sepsis

Healthcare |
edison tv

13.04.22

Recce Pharmaceuticals – executive interview

Team of Research Scientists Working On Computer, with Medical Equipment, Analyzing Blood and Genetic Material Samples with Special Machines in the Modern Laboratory.

Visit Website

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Key Management

James Graham

CEO
Daniel Astudillo

Head of marketing
Dr John Prendergast

Chairman

Balance Sheet

Forecast net debt (A$m)

1.3

Forecast gearing ratio (%)

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(31.9)	(16.8)	(27.7)
Relative	(31.0)	(16.5)	(33.4)
52 week high/low	A$0.8/A$0.5

Financials

Recce Pharmaceuticals is a clinical-stage, Australian biotech company developing a novel class of broad-spectrum synthetic anti-infective drugs to which, so far, all tested bacteria have been unable to develop resistance. This could be a very desirable trait given widespread concerns about antimicrobial resistance. The lead indication for RECCE 327 (R327), is sepsis (Phase I/II study underway), a substantial area of unmet need with significant mortality and high costs of care. Recce is also assessing its intravenous formulation in other indications, such as complicated urinary tract infections. Topical spray and gel formulations of R327 are also being assessed for burn wound infections and diabetic foot infections.